logo
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Business Upturn06-05-2025

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.
All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.
TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05).
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ('Tiziana' or the 'Company'), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced promising results from an open-label clinical study evaluating nasal foralumab, the world's only fully human anti-CD3 monoclonal antibody administered intranasally, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS). This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients suffering from progression independent of relapse activity (PIRA)—a major unmet need in the treatment of MS, and a key disease endpoint for intranasal foralumab development. The article is titled 'Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS.' This study is the first to integrate, F18TSPO PET, Proteomics, and Clinical assessments in na-SPMS. These findings in MFIS score reduction are a critically important Quality of Life (QoL) measure for patients with MS.
Study Highlights: Ten patients with na-SPMS, who continued to progress despite B-cell therapy, were treated with nasal foralumab for a minimum of six months.
No serious or severe treatment-related adverse events were reported.
All patients experienced stabilization of their Expanded Disability Status Scale (EDSS) scores; three of four patients that were treated continuously for 12 months showed improvement.
Fatigue, a major symptom burden in MS, improved in six out of ten patients, as measured by the Modified Fatigue Impact Scale (MFIS).
Total MFIS scores correlated strongly with mGALP scores in the hippocampus (r=0.89, p=0.007) at baseline.
No new T2 lesions were observed on MRI.
TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05).
Single-cell RNA sequencing revealed early and sustained changes in peripheral immune cells, including increased regulatory T cells (Tregs) and expression of TGFβ across multiple cell types.
'Our findings mark a significant advancement for patients living with non-active Secondary Progressive MS, who currently have very limited treatment options,' said Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System. 'Nasal administration of foralumab represents a novel, non-invasive approach that not only induces regulatory immunity but also reduces harmful CNS inflammation.'
PIRA and progressive forms of MS are characterized by central nervous system-centric inflammation driven by microglial activation, processes not adequately addressed by existing therapies. Traditional MS treatments targeting B-cells and cell trafficking have limited efficacy in managing progression behind the blood-brain barrier.
Nasal foralumab leverages the mucosal immune system to induce regulatory immune responses, offering a novel mechanism to suppress CNS inflammation without the systemic immunosuppression seen with intravenous therapies. Previous studies showed that nasal anti-CD3 could treat progressive MS in animal models by expanding LAP+ and IL-10+ Tregs, providing the scientific rationale for this human study.
In parallel with these encouraging results, Tiziana Life Sciences has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial to further assess the efficacy and safety of nasal foralumab in a larger cohort of patients with na-SPMS. This trial is expected to reach top line data read out at the end of 2025.
'We are incredibly excited by these results, which validate the potential of nasal foralumab to fundamentally shift the treatment paradigm for progressive MS,' said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. 'We are also committed to advancing this promising therapy into other larger clinical studies, such as Alzheimer's Disease and ALS as quickly as possible.'
This article has been submitted for peer review, and the full preprint is available here: https://www.medrxiv.org/content/10.1101/2025.04.30.25326602v1
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Tiziana's Annual Report on Form 20-F for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences LtdPaul Spencer, Business Development, and Investor Relations+44 (0) 207 495 2379
email: [email protected]

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nearly 1400 people took part in national ‘Walk MS 2025′
Nearly 1400 people took part in national ‘Walk MS 2025′

Yahoo

time6 hours ago

  • Yahoo

Nearly 1400 people took part in national ‘Walk MS 2025′

Despite a rainy weekend, the weather certainly held out long enough for 'Walk MS 2025.' It's part of a national annual event that raises awareness and funds for the fight against multiple sclerosis. In Boston, participants walked along a one to three-mile route, overlooking the harbor, before finishing up at the UMass Boston campus. Multiple Sclerosis is a disease that affects a person's nervous system. Symptoms can often vary from person to person, including numbness and tingling to mobility challenges, blindness, and paralysis. Multiple Sclerosis affects an estimated 1 million people in the United States. Lori Espino, President of the National MS Society Greater New England Chapter, reflected on the walk. 'We had close to 1400 people come out either supporting a loved one with MS or living with MS themselves, and we raised over half a million dollars for a cure.' Sunday's walk was the sixth held in Massachusetts over the past few months; together, they've raised nearly one million dollars in donations. This is a developing story. Check back for updates as more information becomes available. Download the FREE Boston 25 News app for breaking news alerts. Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW

Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan

Business Wire

time8 hours ago

  • Business Wire

Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ('NIPRO') for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan." Share Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,' said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. 'We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.' About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.

Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells
Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells

Business Upturn

time17 hours ago

  • Business Upturn

Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells

By GlobeNewswire Published on June 8, 2025, 18:00 IST ORLANDO, Fla., June 08, 2025 (GLOBE NEWSWIRE) — Shapellx , a leading women's shapewear brand, proudly announces the launch of OceanHug™ – a seamless women's wear collection of intimates, outerwear, and shapewear pieces crafted with a first-of-its-kind fabric made from recycled oyster shells. The new sustainable, ocean-inspired collection enhances body contours while delivering the perfect balance of style, comfort, and sustainability. Every year, millions of pounds of oyster shells are discarded, eventually ending up in landfills. Shapellx believes that beauty should never come at the expense of the environment. Every OceanHug™ piece gives new purpose to 33 recycled oyster shells, integrating them into ethically produced, performance-driven fabrics. By turning marine waste into innovation, the collection represents a fresh take on circular fashion by finding a second life for shells that promotes innovation while reducing use of virgin materials. 'As sustainability becomes a top priority for both brands and consumers, Shapellx is proud to lead with innovative materials like oyster protein that combine environmental responsibility with performance-enhancing benefits,' said Shane Shi, Vice President of Shapellx. 'We're committed to delivering more sustainable alternatives without compromising on quality or comfort. OceanHug™ is just the beginning.' The lightweight yet form-fitting OceanHug™ yarn is engineered with breathable, moisture-wicking properties, feeling silky, cool, and comfortable to the touch. The fabric uniquely incorporates collagen peptides and oyster protein fiber, rich in amino acids and trace elements, which can help to nourish the skin and strengthen its barrier. OceanHug™ also offers antibacterial properties, reducing harmful bacteria growth by 2.56%, and is specially processed to be free from irritating chemicals, making it an excellent choice for those with sensitive skin. The new lineup, built with shapewear materials to hug and comfortably embrace the body, comes in soft hues of baby blue, lavender pink, oyster white, and more. The collection includes the following products: OceanHug™ Oyster Reborn Smoothing Bodysuit The delicate lace cup edges expand the coverage around the bust, enhancing the natural bust shape and curve. The waist and abdomen shaping works to tighten and smooth targeted areas for a comfortable, sculpted silhouette. Retails for $54 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, lavender pink and bright red. OceanHug™ Oyster Reborn T-Shirt Bra The OceanHug ™ Seamless Bra is made with high-elasticity yarn and butter-soft fabric for an ultimate comfort experience. The fixed one-piece cup design reduces the risk of cup-shifting for a supportive fit. The back closure is 7cm wide, compared to the traditional 3.5cm, providing better wraparound coverage and enhanced smoothing. Retails for $49 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Brief The briefs feature a mid-waist, hip-hugging seamless design for stable coverage, preventing unwanted digging and squeezing while delivering stretch to fit perfectly on all body types. Made from skin-friendly, soft modal fabric, it provides a gentle and refreshing touch on the skin. Retails for $9 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Cami The V-neckline highlights the collarbone, creating a feminine, flattering look. The built-in 3D molded cups comfortably lift and shape the bust for all-day support. It features an anti-slip grip at the bottom hem to prevent rolling and ensure a smooth, stable fit. The compression fabric around the waist and abdomen smooths the area and provides comfortable shaping. Retails for $49 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, beige and lavender pink. To celebrate both the OceanHug™ launch and World Ocean Day on June 8, Shapellx hosted a pop-up event in NoHo, New York. Attendees were able to experience the OceanHug™ fabric firsthand and received a special gift. Designed to suit your everyday life and standout moments, Shapellx's new OceanHug™ collection is available to purchase at . To learn more about the collection and keep up with the brand, follow along on Instagram and TikTok . About Shapellx Shapellx is a full-category shapewear brand built on cutting-edge shaping technology and refined design aesthetics. Through premium international retailers such as Nordstrom and its own online platform, Shapellx connects with women who value both quality and style. The brand is dedicated to meeting the dual needs of fashion expression and body contouring in everyday wear, empowering women to radiate confidence from the inside out. Contact:Melina Schaefer [email protected] A video accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store